Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 1/20 | 0.42 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.40 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CCR8 | P51685 | 1/20 | 0.38 |
| ▸ | RXRA | P19793 | 5/20 | 0.38 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4710916 | 0.92 | HTT (0.39) | AGTR1AGTR2MEN1ALDH1A1KMT2A | |
| SCHEMBL4710917 | 0.87 | LPAR1 (0.41) | MEN1ALDH1A1KMT2ALPAR1HTT | |
| SCHEMBL22163720 | 0.84 | RXRA (0.50) | HTTRXRA | |
| SCHEMBL4710162 | 0.83 | HTT (0.43) | MEN1ALDH1A1KMT2AHTTCYP2C9 | |
| SCHEMBL4760926 | 0.80 | KMT2A (0.40) | MEN1ALDH1A1KMT2AHTTCYP2C9 | |
| SCHEMBL14159946 | 0.76 | CYP26A1 (0.47) | HTTRXRA | |
| SCHEMBL4709673 | 0.73 | MEN1 (0.39) | MEN1ALDH1A1KMT2AHTTRXRA | |
| SCHEMBL14159944 | 0.71 | CYP3A4 (0.48) | MEN1KMT2AHTTCYP2C9 | |
| SCHEMBL14017862 | 0.69 | RXRA (0.46) | MEN1KMT2AHTTRXRA | |
| SCHEMBL4711958 | 0.69 | RXRA (0.46) | MEN1KMT2AHTTRXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1935869-A1 | Retinoids for the treatment of emphysema | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-25 | — | — | EP | disclosed |
| US-6777418-B2 | FOR TREATING OR PREVENTING EMPHYSEMA, CANCER AND DERMATOLOGICAL DISORDERS | SYNTEX (U.S.A.) LLC | 2004-08-17 | — | — | US | disclosed |
| EP-1324970-A2 | RETINOIDS FOR THE TREATMENT OF EMPHYSEMA | F. HOFFMANN-LA ROCHE AG (CH) | 2003-07-09 | — | — | EP | disclosed |
| US-20020082265-A1 | For treating or preventing emphysema, cancer and dermatological disorders | SYNTEX (U.S.A.) LLC | 2002-06-27 | — | — | US | disclosed |
| WO-2002028810-A2 | RETINOIDS FOR THE TREATMENT OF EMPHYSEMA | F. HOFFMANN-LA ROCHE AG (CH) | 2002-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082265-A1 | For treating or preventing emphysema, cancer and dermatological disorders | RXRA, RXRG, RXRB | AGTR1 3253/4885AGTR2 2845/4885MEN1 3005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.